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Background: Next generation targeted resequencing is replacing Sanger sequencing at high pace in routine
genetic diagnosis. The need for well validated, high quality enrichment platforms to complement the bench-top
next generation sequencing devices is high.
Results: We used the WaferGen Smartchip platform to perform highly parallelized PCR based target enrichment for
a set of known cancer genes in a well characterized set of cancer cell lines from the NCI60 panel. Optimization of
PCR assay design and cycling conditions resulted in a high enrichment efficiency. We provide proof of a high
mutation rediscovery rate and have included technical replicates to enable SNP calling validation demonstrating
the high reproducibility of our enrichment platform.
Conclusions: Here we present our custom developed quantitative PCR based target enrichment platform. Using
highly parallel nanoliter singleplex PCR reactions makes this a flexible and efficient platform. The high mutation
validation rate shows this platform’s promise as a targeted resequencing method for multi-gene routine sequencing
diagnostics.
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The advent of next generation sequencing technology
has unleashed a wealth of targeted resequencing experi-
ments in all fields of genomics [1]. The field of multi-
gene disease diagnostic sequencing is changing rapidly
with a shift from conventional Sanger sequencing to tar-
geted next generation sequencing. In addition, many re-
searchers face the daunting task of validating large sets
of genomic variants resulting form large scale resequen-
cing studies that investigate the human exome or whole
genome [2-5]. Sanger sequencing has long been the gold
standard sequencing technology and remains an import-
ant method for small scale sequencing experiments and
routine genetic diagnostics. Compared to next generation
sequencing, Sanger sequencing is a labor intensive and
relatively expensive technology. Both the PCR sequencing
reaction and interpretation of the sequencing trace files are* Correspondence: Joke.Vandesompele@ugent.be
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reproduction in any medium, provided the ora time consuming processes making Sanger not the most
ideal technology for multi-gene studies or large scale vari-
ant confirmation. Even for a diagnostic target for which
validated sequencing assays are available, interpretation of
the Sanger trace file is a semi-automatic process at best,
often requiring human review (see Mitchelson et al. for re-
view) [6,7]. More so, in many genetic studies sample het-
erogeneity or exceptions to the classical bi-allelic state of
the genome make this analysis even more challenging, if
not impossible.
Next generation sequencing can tackle most of these
challenges. The release of bench-top scale sequencing
machines has paved the way to multi-gene targeted next
generation sequencing diagnostics. The challenge of the
upfront target enrichment has now become the bottle-
neck for many sequencing applications. Many probe or
PCR based single tube sequence capture techniques cur-
rently exist. These methods typically require extensive
optimization to reach the quality standards set in many
Sanger sequencing diagnostic facilities. Most diagnostic
labs have already invested in the optimization of PCRal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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problematic to perform this optimization again in order
to switch sequencing platforms.
Here, we present a new platform for detecting genetic
variants directed at multi-gene disease diagnostics. By op-
timizing several steps in a custom PCR based sequence
enrichment strategy and upscaling this strategy using a
highly parallel nanoliter quantitative PCR instrument, we
developed a highly flexible enrichment protocol that has a
high efficiency, a near perfect target specificity and scales
to address the challenges discussed earlier. Our workflow
allows the selective resequencing of hundreds to a few
thousands of targets in a single analysis, greatly reducing
the overall validation cost and effort. It even allows the
researcher to re-use previously optimized assays in a
highly parallel fashion. In a proof of concept study, we
have rediscovered known mutations in well characterized
cancer cell lines. In addition, we have used objective qual-
ity parameters that enable transparent and robust inter-
platform comparisons.
Methods
For this technical proof of concept study we aimed at
resequencing a set of genes known to be mutated in can-
cer samples. We selected 15 cell lines from the NCI60
panel [8] for which high quality mutation data are made
available through the cosmic database [9] for a large list
of known cancer genes.
Samples
A selection of 15 cancer cell lines and 2 normal control
samples were included in this study (Table 1). In addition,
the enrichment was repeated on the two normal control
samples and one of the cell lines (MCF7) to evaluate the
technical reproducibility of the platform. A total of 360 pg
of input DNA (~112 gene copies) was used per nanoliter
PCR reaction.
Enrichment platform
The SmartChip nanowell platform (WaferGen Biosystems)
is an ultra-high throughput quantitative PCR (qPCR) plat-
form used for large scale gene expression studies or digital
PCR. To address the problem of PCR product collection,
WaferGen Biosystems specifically developed a capture sys-
tem for the nanowell SmartChip. By reverse centrifuging
of the capture chips in custom capture devices, PCR prod-
ucts were collected from the nanowell chips. A prototype
capture device for the 5184 reaction well chips has been
used in some preliminary testing, but for this study we
have used a 4 quadrant chip layout (841 wells per quad-
rant, see Figure 1) and the matching disposable extraction
fixtures to perform target capture of up to 4 samples on a
single chip. Evidently, any combination of samples and
amplicons is possible; ranging from 4 times a maximum of841 amplicons, 2 times up to 1682 amplicons or 1 time
3364 amplicons, allowing for a maximum in experimen-
tal flexibility. The MyDesign dispenser provides exact
control over the dispensing of primers and samples in
the reaction wells.
Target enrichment
A list of 16 known cancer genes with diagnostic rele-
vance was selected for resequencing (Table 2). The genes
were selected to harbor mutations in the selected NCI60
cell lines. Primers were designed to amplify all exons of
the genes using primerXL, our quantitative PCR primer
design tool adapted for resequencing primer design (www.
primerxl.org) (Lefever et al., in preparation). A total of 376
amplicons were designed using tiling settings, taking into
account known SNP positions and with a target annealing
temperature of 60°C. The average amplicon length is 441
basepairs (bp) with a range of 319 to 745 bp. Primer and
amplicon information is listed in Additional file 1. The
total target region comprised of 165 811 bp. Primers
were ordered from Integrated DNA Technologies.
Dispensing of the reaction components in the SmartChip
reaction wells is a 2 step process performed on the
SmartChip Multiplesample Nanodispenser. The first step
is the dispensing of 50 nl of a primer-combination. For this
a 500 nM primer and 2X Bio-Rad SsoAdvanced SYBR
PCR mastermix solution is presented in a 384 well plate
format to the Nanodispeser machine and dispensed on
the SmartChip wells. The second step consists of the
dispensing of another 50 nl of a 7.2 ng/μl sample DNA
solution to the nanowells containing the primer master-
mix combination. The final reaction volume of 100 nl
consists of 360 pg of template DNA and 250 nM of for-
ward and reverse primer in a 1X mastermix solution. A
rough visual quality control of the dispensing steps is
carried out by visualizing the nanowell chips by means
of a magnifying glass.
With 376 targets in this experiment we were able to
use the 4 quadrant nanowell chips to capture 4 samples
per chip. The primers were spotted in duplicate for most
of the samples. Some samples were repeated with singlet
PCR reaction per chip to evaluate both amplification
and DNA extraction efficiency and reproducibility; un-
used wells were left empty (see Table 3 for experimental
replicate configuration).
SmartChips containing the assay and samples were cy-
cled in the SmartChip Cycler (WaferGen Biosystems) using
the following thermal parameters: 3 minutes at 95°C,
40 cycles composed of 30 seconds at 95°C and 60 sec-
onds at 60°C. This amplification protocol was optimized
for sequence enrichment of long PCR fragments and is
deviant from the default qPCR protocol in that it has a
significantly longer annealing/extension phase. Immedi-
ately following amplification, melt curve analysis was
Table 1 Samples and known mutations
Samples Mutations:
Name Type Gene name Genomic location cDNA position Protein position
BT-549 Breast cancer cell line PTEN 10:89720672 c.823delG p.V275fs*1
CCRF-CEM Leukemia cancer cell ine CDKN2A 9:21968228 c.1_471del471
9:21971002 c.317_522del206
MLH1 3:37042536 c.298C > T p.R100*
3:37056036 c.790 + 1G > A
NOTCH1 9:139399362 c.4783_4784ins36 p.R1595 > PRLPHNSSFHFLR
PTEN 10:89653782 c.80_492del413
HCT116 Colon cancer cell line CDKN2A 9:21974758 c.68_69insG p.R24fs*20
9:21994234 c.220_220delG p.E74fs*15
MLH1 3:37056000 c.755C > A p.S252*
IGROV-1 Ovarian cancer cell ine MLH1 3:37070378 c.1513delA p.S505fs*3
MSH6 2:48030647 c.3261delC p.F1088fs*2
PC3 Prostate cancer cell line PTEN 10:89685270 c.165_1212del1048 p.R55fs*1
SN12C Kidney cancer cell line NF2 22:30032739 c.115-1G > C
786-O Kidney cancer cell line CDKN2A 9:21974677 c.1_150del150
9:21984138-21984453 c.1_316del316
PTEN 10:89692961 c.445C > T p.Q149*
VHL 3:10183842 c.311delG p.G104fs*55
ACHN Kidney cancer cell line CDKN2A 9:21968228 c.1_471del471
9:21971002 c.317_522del206
NF2 22:30032794 c.169C > T p.R57*
DU-145 Prostate cancer cell line CDKN2A 9:21971108 c.250G > T p.D84Y
MLH1 3:37038108 c.117-2A > T
HCT-15 Colon cancer cell line APC 5:112177787 c.6496C > T p.R2166*
5:112175539 c.4248delC p.I1417fs*2
BRCA2 13:32913837 c.5351delA p.N1784fs*7
13:32913837 c.3599_3600delGT p.C1200fs*1
MSH6 2:48032121 c.3511_3516 > T p.D1171fs*4
2:48025990 c.868delC p.L290fs*1
HT-29 Colon cancer cell line APC 5:112173848 c.2557G > T p.E853*
5:112175957 c.4666_4667insA p.T1556fs*3
MCF7 Breast cancer cell line CDKN2A 9:21971002 c.317_522del206
9:21968228 c.1_471del471
MDA-MB-231 Breast cancer cell line CDKN2A 9:21967751 c.1_522del522
9:21968228 c.1_471del471
NF2 22:30057209 c.691G > T p.E231*
MOLT-4 Leukemia cancer cell line CDKN2A 9:21967751 c.1_522del522
9:21968228 c.1_471del471
NOTCH1 9:139390649 c.7544_7545delCT p.P2515fs*4
PTEN 10:89717775. c.800delA p.K267fs*9
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Table 1 Samples and known mutations (Continued)
OVCAR-5 Ovarian cancer cell line CDKN2A 9:21967751 c.1_522del522
9:21968228 c.1_471del471
Normal1 Healthy normal1 control DNA
Normal2 Healthy normal2 control DNA
NCI60 cell lines and normal control DNA samples included in this study with a list of known mutations per cel line.
In nonsense or frameshift mutations the *symbol indicates the loss of the amino acid coding potential of the DNA sequence.
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4 disposable extraction fixtures were attached to each
SmartChip, one fixture per quadrant, and PCR products
were collected in 0.2 ml PCR tubes by means of centrifu-
gation (1 sample per tube) at 3500 rpm for 15 minutes.
Library preparation and sequencing
PCR pools were purified using AMPure beads XT
(Beckman Coulter). The concentration of each pool was
measured using the dsDNA assay kit on the Qubit
fluorometer (Invitrogen) and fragment analysis occurred
on a BioAnalyzer 2100 using the high sensitivity chip
(Agilent). Library preparation and sequencing was carried
out by the Nucleomics core facility at the Flemisch insti-
tute for biotechnology (VIB). Nextera XT (Illumina) library
preparation on all 24 PCR pools occurred following
the manufacturers recommendation using 1 ng of each
sample pool as input. In short the Nextera transposaseFigure 1 Nanowell chip. 4 quadrant nanowell chip used in this experimeensures random fragmentation and adaptor ligation to the
amplicons after which a dual barcoding occurred during
amplification, followed by purification on AMPure beads.
The molarity of each library was determined using the
concentration (measured by Qubit) and fragment length
(BioAnalyzer). Libraries were diluted to equal molarity
and finally pooled by using equal volumes of each library.
This sequencing pool was diluted to 10 nM, and finally
95% of sequencing pool (6 pM) and 5% of Phix control
(8 pM) were mixed and loaded into the flowcell of a
MiSeq (Illumina) instrument. Sequencing was performed
for 150 bp in paired end mode.
Data analysis
Raw sequencing data was demultiplexed on the MiSeq
instrument using the manufacturer’s software. Of the 23
076 775 reads obtained, 1.6% were lost due to an
unrecognizable index. The sequencing resulted in annt.
Table 2 Genes and target regions
Name Ensembl ID Number of exons Target region Number of primers Capture size (bp)
BRCA1 ENSG00000012048 12 1693 33 14202
MLH1 ENSG00000076242 16 6025 18 7416
PALB2 ENSG00000083093 9 9027 19 8072
MSH2 ENSG00000095002 8 4605 20 8095
TGFBR1 ENSG00000106799 63 13147 25 11159
PHOX2B ENSG00000109132 34 9371 4 2028
MSH6 ENSG00000116062 27 10930 16 7441
VHL ENSG00000134086 16 10701 4 1896
APC ENSG00000134982 3 3737 35 15085
BRCA2 ENSG00000139618 10 4328 43 20068
NOTCH1 ENSG00000148400 3 538 32 16514
ATM ENSG00000149311 3 565 63 26598
TGFBR2 ENSG00000163513 16 3307 19 7987
PTEN ENSG00000171862 13 4003 10 4329
NF2 ENSG00000186575 4 342 17 6972
FLCN ENSG00000264187 12 1495 13 5586
Total 249 83814 371 163448
List of the genes targeted, their Ensembl gene id, number of exons and target size.
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237–1 608 833, see Table 3 for reads per sample). Map-
ping was performed to build 37 of the human reference
genome (Genome reference consortium GRCh37) using
BWA [10] (v. 0.5.9). Reads were quality recalibrated using
the Genome analysis toolkit [11] (v. 1.6-13-g91f02df) and
duplicate reads were removed using Picard tools (v. 1.59).
Variants were called using the Genome Analysis Tool-
kit unified genotyper [11] (v 1.6-13-g91f02df). Variants
were annotated and sample calls were compared using
our custom cloud based analysis platform seqplorer (www.
seqplorer.org) (De Wilde et al., in preparation).
Coverage data was extracted for each sample using
samtools depth option on each genomic position. Both
the amplicon locations and the coding exon locations of
genes captured in this experiment were used as the target
locations for calculating the coverage statistics as indi-
cated in the results section. As our goal was to evaluate
the capture platform and not the subsequent library prep
and sample pooling we eliminated the inter-sample cover-
age by normalizing the coverage for each position by the
mean coverage per sample.
Further statistical analysis and plotting of coverage data
was done using the R language and environment for stat-
istical computing (R version 2.15.1; www.R-project.org).
Results and discussion
To evaluate the overall technical performance, efficiency
and reproducibility of this novel PCR based sequence en-
richment platform we included several levels of qualitycontrol. First, through the resequencing of known cancer
genes on a set of cancer cell lines with known mutation
status, we were able to evaluate the rediscovery rate. Sec-
ond, SNP calls were compared to public datasets to assess
accuracy or compared between replicated samples to
evaluate the reproducibility of the variant calling. Third,
an objective coverage evaluation among technical repli-
cates as well as different samples was performed.
qPCR performance metrics
One of the advantages of using a massively parallel quanti-
tative PCR platform for target capture is the upfront qual-
ity check that can be performed on the amplification
curves. All chip amplification curve profiles looked satis-
factory with only 1.16% reaction dropout (defined as a
Cq > 29). Although a weak correlation exists between the
Cq value of the amplification reaction and the amplicon
coverage (R2 = 0.216), no clear correlation was observed
between either amplicon length or end-point fluorescence
and sequence coverage. Overlapping or tiling assays were
excluded from this analysis as the coverage cannot be un-
ambiguously attributed to one of the overlapping assays.
Coverage analysis
We obtained roughly 0.95 (stdev 0.3) million reads per
sample. Almost all the reads were mappable to the refer-
ence genome and 78.6% (stdev 3%) mapped back to the
target region. On average, 15.2% (stdev 3%) of PCR du-
plicates were present. The success rate in the assay de-
sign and target capture was 93.6% as defined by the
Table 3 Experimental duplicate layout, read and coverage statistics
Sample Number
of PCR
replicates
Total
number of
reads
Mapped On
target
PCR
duplicates
Amplicon Exon
Mean
coverage
Standard
deviation
Mean
coverage
Standard
deviation
Normal1-duplicate-B 2 951169 97.7% 79.0% 15.6% 542.7 334.9 427.9 409.4
BT-549 2 1031471 97.4% 77.9% 16.6% 567.7 365.2 451.1 436.8
CCRF-CEM 2 894547 97.7% 76.4% 15.2% 498.4 356.9 403.3 413.9
HCT-15 2 826606 97.7% 80.3% 14.0% 486.5 327.9 384.1 387.4
MOLT-4 2 1271883 97.9% 77.3% 17.2% 747.0 460.3 589.9 561.2
HCT116 2 1384151 97.7% 72.0% 21.0% 724.4 524.5 589.1 609.5
Normal1-duplicate-A 2 1608833 97.9% 74.3% 20.6% 877.3 536.2 692.3 658.2
SN12C 2 472237 97.8% 84.7% 9.8% 294.1 199.9 233.5 233.6
IGROV-1 2 672337 97.8% 79.7% 11.6% 404.9 281.6 325.8 329.2
DU-145 2 723007 97.8% 82.1% 12.3% 434.7 273.1 346.9 332.1
MDA-MB-231 2 769668 97.7% 81.2% 13.2% 461.8 315.7 367.6 373.4
OVCAR-5 2 659926 97.3% 81.1% 13.1% 386.5 293.4 308.1 332.7
786-O 2 1167234 97.9% 79.1% 17.2% 684.6 463.9 543.9 549.2
MCF7-B 2 1053960 97.8% 77.8% 17.3% 588.1 398.9 472.1 473.4
PC3 2 566416 97.8% 79.9% 11.5% 329.9 252.1 267.3 287.9
MCF7-A 2 1299077 97.6% 76.0% 19.3% 703.5 465.2 569.0 558.0
RPMI-8226 1 1037872 97.5% 77.2% 16.9% 575.4 394.6 462.1 461.8
Normal2-singleton-A 1 806612 97.7% 79.9% 14.5% 461.2 296.8 367.2 355.5
MCF7 1 1193431 97.6% 75.3% 18.2% 647.8 441.9 515.4 513.5
Normal1-singleton-A 1 1227019 97.9% 74.7% 17.3% 688.5 450.0 543.0 533.9
Normal2-singelton-B 1 571558 97.7% 82.8% 11.3% 340.9 227.4 274.5 268.0
HT-29 1 578229 97.8% 81.7% 11.6% 340.1 243.2 273.1 280.7
Normal1-singleton-B 1 1070055 97.8% 75.9% 15.6% 615.2 393.4 488.2 472.0
ACHN 1 853092 97.8% 79.2% 14.9% 486.6 327.2 387.2 384.2
Mean 945432.9 97.7% 78.6% 15.2% 537.0 359.3 428.4 425.6
Stadard deviation 296401.9 0.1% 3.0% 3.0% 153.0 94.2 121.2 115.0
The number of PCR replicates performed on the capture chip for each target per sample. The number of reads obtained during the sequencing and the coverage
this resulted in.
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more than 80% of the samples. 96.4% of the assays re-
sulted in coverage in at least one of the samples. As the
coverage is a function of the number of reads obtained
for a given sample (see Table 3 for detailed per sample
read and coverage statistics), data were normalized by
dividing the coverage of each base by the mean coverage
for that sample. In this way, we can compare the coverage
statistics over the samples and evaluate the variation in
coverage attributable to the capture platform. Figure 2A
and B show the normalized coverage over the amplicons
and targeted exons, respectively, and demonstrate that the
uniformity and reproducibility of the capture platform is
extremely good. 88.7% of the exonic bases receive a cover-
age between 0.2 and 5 times the mean coverage and 78.1%of the exonic bases fall within a two fold coverage range
around the mean.
The high reproducibility of the target capture across the
samples is demonstrated by the high average Spearman
rank correlation of 0.892 (standard deviation of 0.038) be-
tween the coverage values for any two different samples
(see Table 4). Figure 3 shows the correlation between the
technical replicates. No difference in coverage correlation
is apparent between the duplicate and singleton PCR cap-
ture reactions.
Mutation rediscovery
The NCI-60 cell lines analyzed in this study contain in total
25 well documented mutations [12] in the targeted genes
from our resequencing experiment (Cosmic database,
A B
Figure 2 Mean normalized coverage distribution. Cumulative distribution plot of mean normalized coverage for the capture amplicons (A)
and the exons of the genes targeted (B).
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samples PC3 and CCRF-CEM are large homozygous de-
letions. A lack of coverage at these positions is expected.
For 22 of the 23 remaining variant positions, we ob-
tained sufficient coverage (> 20 fold) to perform reliable
variant calling, 21 of these variants are clearly present in
the raw sequencing data. One variant was present in the
sequencing data but with a coverage of 9 times, preclud-
ing reliable variant calling at this position. An overview
of mutations and their validation status is available in
Table 5. The 2 large homozygously deleted positions in
the PTEN gene can be confirmed from the sequencing
as well as the qPCR amplification data. Table 6 shows
adequate end point fluorescence and Cq values as well
as good coverage for the PTEN-4 amplicon comprising
the deletion in all but the 2 deleted samples (CCRF-
CEM and PC3). Summarizing, the mutation validation
rate for this experiment is 23 out of 25 (92%). The only
mutation that was missed is designated as complex in
the Cosmic database and probably comprises of an inter-
chromosomal rearrangement; PCR amplification of the
variant allele is impossible with our targeted primer pair.
As this variant is heterozygous, the reference allele is amp-
lified, so no deletion is detected by qPCR and the sequen-
cing data only shows the reference allele. Of note is that
the 2 deletions in the PTEN gene detected in this data-
set are homozygous deletions. A PCR based enrichment
technique is probably unable to detect a large heterozy-
gous deletion.
SNP detection
As a measure of enrichment platform reproducibility and
accuracy, the number of correctly called known SNPs is
used. The SNP status of the NCI-60 samples is available
from the Developmental Therapeutics Program (DTP)
website (http://dtp.nci.nih.gov/index.html) as published by
[13]. Unfortunately, only 6 SNPs on the Affymetrix 125 K
platform fall within the target region of our capture. Forthese 6 SNPs, the genotype call in the publicly available
data was compared to the genotype calls in the 16 NCI-60
samples in our dataset and concurred in 95.6% of the
cases. Of the non-concordant SNP calls, 3 occurred in one
and the same sample (SN12C) suggesting that a sample
naming mix-up might be the cause of this mismatch. We
were able to confirm the NF2 mutation in this sample as
described by the Cosmic database thus indicating our
sample id agreed with that used in the Cosmic database
and leading us to doubt the sample id mentioned in the
DTP dataset.
A second set of SNP calls is available from an exome se-
quencing study [14]. We downloaded the variants in the
genes included in our target enrichment experiment from
the CellMiner tool (http://discover.nci.nih.gov/cellminer/).
A total of 473 variants were found in the exome dataset
with a genomic position in the target region enriched in
our experiment. Of these variants 431 (91.1% with a
standard deviation of 5.85% over the 15 cell lines in-
cluded) were called from our targeted resequencing ex-
periment. From the downloaded data, Abaan et al. do
not provide genotype calls but rather variant to refer-
ence read ratios. Markedly, the average difference in the
variant to reference ratio at each variant position for
these two datasets is only half a percentage (0.544%, SD
0.11%) leading us to conclude that genotype calling
from our platform is highly congruent with the geno-
types called from the exome sequencing dataset if simi-
lar algorithms were used in genotype calling.
To increase the number of SNPs in this analysis, we ex-
amined the SNP calls for the technical replicates. This
analysis not only depends on the accuracy of the capture
and the correct co-amplification of both alleles of hetero-
zygous positions, but also on the algorithms used to per-
form the variant calling. To evaluate the capture platform
as objectively as possible (with as little as possible interfer-
ence of the variant calling algorithm), we looked at the
raw variant coverage data for all known polymorphisms
Table 4 Coverage correlation
PC3 MCF7GhentB ACHN 786-
O
Normal1-
singleton-
B
OVCAR-
5
MDA-
MB-
231
DU-
145
IGROV-
1
SN12C Normal1-
duplicate-
A
HT-
29
HCT116 MOLT-
4
HCT-
15
Normal2-
singleton-
B
CCRF-
CEM
Normal1-
singleton-
A
BT-
549
MCF7 Normal2-
singleton-
A
RPMI-
8226
MCF7GhentB 0.884
ACHN 0.872 0.910
786-O 0.844 0.864 0.865
Normal1-
singleton-B
0.843 0.901 0.932 0.870
OVCAR-5 0.798 0.799 0.825 0.904 0.804
MDA-MB-
231
0.846 0.861 0.864 0.965 0.861 0.936
DU-145 0.877 0.909 0.919 0.928 0.920 0.887 0.940
IGROV-1 0.926 0.905 0.900 0.892 0.887 0.798 0.865 0.910
SN12C 0.882 0.901 0.914 0.910 0.902 0.928 0.935 0.953 0.894
Normal1-
duplicate-A
0.840 0.945 0.902 0.885 0.915 0.794 0.863 0.916 0.890 0.886
HT-29 0.851 0.888 0.939 0.832 0.924 0.812 0.855 0.890 0.869 0.896 0.868
HCT116 0.946 0.911 0.907 0.887 0.880 0.816 0.875 0.911 0.975 0.906 0.881 0.877
MOLT-4 0.858 0.904 0.900 0.938 0.919 0.853 0.928 0.965 0.917 0.933 0.933 0.864 0.910
HCT-15 0.833 0.852 0.867 0.969 0.858 0.927 0.975 0.938 0.870 0.919 0.868 0.838 0.872 0.931
Normal2-
singleton-B
0.842 0.883 0.931 0.832 0.915 0.836 0.854 0.903 0.856 0.906 0.869 0.933 0.867 0.875 0.844
CCRF-CEM 0.959 0.907 0.909 0.870 0.876 0.817 0.865 0.907 0.948 0.902 0.868 0.880 0.960 0.891 0.863 0.881
Normal1-
singleton-A
0.832 0.897 0.932 0.864 0.950 0.805 0.859 0.908 0.883 0.901 0.910 0.925 0.879 0.919 0.855 0.913 0.871
BT-549 0.859 0.887 0.903 0.900 0.894 0.933 0.928 0.950 0.867 0.963 0.881 0.891 0.883 0.917 0.913 0.912 0.889 0.889
MCF7 0.840 0.878 0.945 0.827 0.918 0.857 0.855 0.896 0.846 0.919 0.863 0.948 0.865 0.861 0.836 0.942 0.871 0.922 0.928
Normal2-
singleton-A
0.861 0.908 0.957 0.855 0.944 0.826 0.865 0.923 0.885 0.913 0.901 0.941 0.892 0.899 0.862 0.946 0.898 0.936 0.913 0.946
RPMI-8226 0.855 0.876 0.945 0.824 0.912 0.838 0.853 0.893 0.846 0.899 0.858 0.950 0.870 0.852 0.839 0.945 0.882 0.910 0.915 0.966 0.956
Normal1-
duplicate-B
0.860 0.951 0.917 0.884 0.918 0.829 0.879 0.931 0.889 0.914 0.973 0.893 0.890 0.924 0.880 0.900 0.890 0.914 0.910 0.897 0.922 0.889
Mean 0.892
Stdev 0.038
Spearman rank correlation of the per base coverage in between all pairs of individual captures reactions.
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http://www.biomedcentral.com/1471-2164/15/184(known to dbSNP build 132) in the target region with a
coverage of at least 20 and a variant allele called by the
genome analysis toolkit in at least one of the technical
replicates. For each of these positions, the genotype call
was compared in all technical replicates and the raw
coverage data was examined (see overview in Table 7 and
detailed figures in Additional file 2). For 3 of the samples,
technical replicates of the capture and sequencing were
performed. These technical replicates deliberately consist
of either singleton or duplicate capture PCR reactions on
the capture chip to examine if capture efficiency and al-
lelic ratio is depending on the number of PCR replicates
in the same chip.
Four capture reactions (2 singleton and 2 duplicate)
were carried out on the normal1 reference DNA sample.
168 variants were detected in at least one of the repli-
cates, of which 15 indels. 120 (71.4%) of these variants
(including 10 indels) were detected in all 4 of the repli-
cates of which only 2 showed a discordance in genotype
call (heterozygous vs homozygous) in one of the 4 repli-
cates. Of the 48 variant positions with an inconsistent
call in the 4 replicates we closely examined the reason
for this discordance from the raw sequencing data. For 5
of the variant positions, the coverage obtained in one or
more of the samples was insufficient to perform a vari-
ant call. Another five of the 48 variant positions reside
in an oligonuleotide repeat (poly N or dinucleotide re-
peat stretch), traditionally associated with false positive
and negative variant calls. For the remaining 38 variant
positions, there was a loss or gain of variant information
due to changes in the allelic ratio between the reference
and variant allele in the replicates. For the MCF7 cell line
sample, 3 capture reactions were carried out of which 1
singleton and 2 duplicates PCR captures. For this sample
86 SNP positions (16 indels) were called variant in at least
one of the replicates of which 72 (83.7%) (including 10
indels) are common amongst all three replicates, 3 of
which showed a discordant genotype call in one of the
samples. Again we carefully examined the allele ratio in all
3 replicates of the 14 SNP positions not called consistently
in the replicates. Five miscalls could be attributed to gen-
omic repeats at the SNP position. Four could not be called
in one or more of the samples due to coverage issues. The
remaining 5 were either missed or false positive calls in
one of the samples due to a low or borderline coverage for
the variant allele in the sample. Excluding the miscalled
positions in the repeat regions we can conclude that for
the 243 allele calls made for SNPs in the 3 technical repli-
cates, 6 calls (2.4%) could not be made due to coverage is-
sues and 7 (2.9%) appeared dubious due to allelic ratio
issues. Performing the same analysis for the normal2
reference DNA sample, we found a total of 149 SNP (14
indel) positions of which 121 (81.2%) (11 indel) were in
common between the 2 replicates with only 2 of thesenot having a concordant genotype. We found 3 SNPs to
be in a repeat region, 25 allelic ratio problems and no
coverage problems; concluding to allelic ratio issues oc-
curring in 25 out of 292 (total number of SNP calls in
both replicates, not in repeat regions) allele calls (8.5%)
in these replicates.
Concluding the SNP calling data on the technical repli-
cates, we have a total of 1228 SNP positions (the sum of
the number of SNP positions per sample across the repli-
cates times the number of replicates for that sample) in all
the technical replicates. Only 14 SNP calls (1.1%) could
not be made due to coverage issues (this is independent
from the capture being performed by single or duplicate
PCR reactions). 9.2% of the SNP calls could not be made
due to a difference in the allelic ratio (for ease of counting
we assume the SNP call not being made due to an allelic
loss as opposed to a false positive call at the variant pos-
ition having occurred). Upon separate analysis of singleton
vs duplicate PCR replicate capture reactions, we observed
a slightly higher (non-significant) number of these types
of errors occurring in the singleton, namely 8.1% or 33
out of 305 of the SNPs, versus 5.2% or 21 of 232 of the
SNPs for the duplicate PCR reaction captures (Chi
squared test p > 0.05). We can conclude that only a
minor fraction of SNP positions could not be called due
to coverage issues and there is no influence on SNP call-
ing based on the number of PCR enrichment reactions.
As we have no arguments to state that the enrichment
should be performed in duplicate, we conclude that the
nanowell PCR capture is highly reproducible and reli-
able for singleton PCR reactions. We do see some issues
with technical reproducibility of allele calling on our plat-
form due to variable allelic ratio of heterozygous SNP po-
sitions. Unfortunately, we cannot compare our data with
that of other capture platforms as no detailed analysis like
this has been published for any of these platforms.
Conclusions
Today, three different sequence enrichment methodologies
are available [15]: the PCR based (Access Array by
Fluidigm, Directseq by Raindance Technologies and
Ampliseq by Life Technologies), hybridization based
(Sureselect by Agilent and Nimblegen by Roche) and
hybridization-extension based (Haloplex by Agilent and
Truseq by Illumina) methods. Each of these technologies
has its strengths and limitations. PCR based methods are
generally accepted to have the best overall sensitivity and
specificity but are limited in target size mainly due to
the primer cost [16]. The PCR based platforms thus are
targeted towards the diagnostic resequencing market
where primers can be reused. The pure hybridization
based approaches are unable to capture some types of
regions, mainly due to probe design issues around gen-
omic repeats and pseudogenes, but scale easily and thus
Figure 3 Technical replicate coverage correlation. Per base coverage correlation plot and spearman rank correlation values (red) for technical
capture replicates.
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applications [15].
The hybridization-extension based technology from
Agilent (Haloplex) and Illumina (Truseq) are both avail-
able for small targeted resequencing experiments as well
as for whole exome resequencing. At the time of writing,
experience with these novel platforms is limited so no
solid data on their real life performance is available in
the literature.
In this study we demonstrate a novel quantitative PCR
based sequence capture platform that has distinctive ad-
vantages over the currently existing capture platforms.
With up to 5000 reaction wells per chip and the possi-
bility to efficiently amplify amplicons with a large range
in length, the maximum capture target size is similar to
both the Ampliseq and Raindance platforms and is sur-
passing the Fluidigm array based platform that is limited
to 96 individual assays. However, similar to the Fluidim
platform and in contrast to the Ampliseq and Raindance
platforms, the new platform also offers a large flexibility
in experimental design. In contrast to capture reactions
that are carried out in a single invariable multiplexed reac-
tion, the chip based amplification allows a flexible com-
bination of samples and amplicons without interference.
Other similar chip based platforms have already been de-
scribed and have proven their reliability [17,18]. But none
have ever been used to perform sequence capture.There is only scarce amount of literature available
comparing the performance statistics of the above refer-
enced platforms. Jones et al. [19] report a targeted rese-
quencing of 24 genes involved in congenital disorders of
glycosilation in 12 positive control patient samples on
both the Raindance and Fluidigm platform. A perfect
mutation detection rate is reported for both. A direct
comparison of the performance of these platforms with
our dataset is not possible due to the differences in tar-
get region, sequencing and analysis strategy. The re-
ported exon failure rates (low or no coverage) of 15 out
of 225 (6.9%) for Raindance and 13 out of 215 (6.0%) for
Fluidigm are quite similar to the failure rate observed in
our experiments. The Fluidigm platform is also exten-
sively evaluated in a study of mutation discovery in pa-
tients with nephronophthisis-associated ciliopathy (11
genes in 192 patients) [20]. The authors report a mutation
validation rate of 90% and a 93.2% exon capture success
rate as defined by a coverage > 30 fold. Other real life but
smaller gene set coverage statistics for the Fluidigm plat-
form are reported by Hollants et al. [21]; 37 of 38 (97%)
amplicons captured successfully and Schlipf et al. [22]
with 15 of 17 (88%) amplicons captured successfully.
None of the above referenced studies evaluate the
coverage uniformity as a metric. The Raindance capture
platform is evaluated in several studies. Hu et al. have
selectively resequenced 86 genes implicated in X linked
Table 5 Mutation validation
Gene Cel line Position (prot) Position (cdna) Position
(genome)
QPCR
amplification
call
RAW
sequencing
data
Reference
coverage
Variant
coverage
APC HT-29 p.E853* c.2557G > T 5:112173848 OK Yes 428 214
APC HCT-15 p.I1417fs*2 c.4248delC 5:112175539 OK Yes 2 963
APC HT-29 p.T1556fs*3 c.4666_4667insA 5:112175957 OK Yes 608 355
APC HCT-15 p.R2166* c.6496C > T 5:112177787 OK Yes 247 360
BRCA2 HCT-15 p.C1200fs*1 c.3599_3600delGT 13:32912089 OK Yes 165 114
BRCA2 HCT-15 p.N1784fs*7 c.5351delA 13:32913837 OK Yes 272 302
MLH1 DU-145 p.? c.117-2A > T 3:37038108 OK Yes 0 476
MLH1 IGROV-1 p.S505fs*3 c.1513delA 3:37070378 OK Yes 5 605
MLH1 CCRF-CEM p.R100* c.298C > T 3:37042536 OK Yes 354 400
MLH1 HCT116 p.S252* c.755C > A 3:37056000 OK Yes 0 30
MLH1 CCRF-CEM p.? c.790 + 1G > A 3:37056036 OK Low coverage 3 6
MSH6 IGROV-1 p.F1088fs*2 c.3261delC 2:48030647 OK Yes 65 650
MSH6 HCT-15 p.D1171fs*4 c.3511_3516 > T 2:48032121 OK No (complex?) 551 0
MSH6 HCT-15 p.L290fs*1 c.868delC 2:48025990 OK Yes 214 230
NF2 SN12C p.? c.115-1G > C 22:30032739 OK Yes 0 599
NF2 ACHN p.R57* c.169C > T 22:30032794 OK Yes 2 772
NF2 MDA-MB-231 p.E231* c.691G > T 22:30057209 OK Yes 1 817
NOTCH1 CCRF-CEM p.R1595 > PRLPHNSSFHFLR c.4783_4784ins36 9:139399362 OK Yes 96 23
NOTCH1 MOLT-4 p.P2515fs*4 c.7544_7545delCT 9:139390649 OK Yes 143 155
PTEN PC3 p.R55fs*1 c.165_1212del1048 10:89685270 Deletion No coverage 0 0
PTEN 786-O p.Q149* c.445C > T 10:89692961 OK Yes 0 910
PTEN CCRF-CEM p.? c.80_492del413 10:89653782 Deletion No coverage 0 0
PTEN MOLT-4 p.K267fs*9 c.800delA 10:89717775. OK Yes 34 1499
PTEN BT-549 p.V275fs*1 c.823delG 10:89720672 OK Yes 3 159
VHL 786-O p.G104fs*55 c.311delG 3:10183842 OK Yes 5 250
Validation rates for all mutations in the NCI60 cell lines included in this publication. The number of reads on the reference and variant bases for each variant
position are given in the last 2 columns.
In nonsense or frameshift mutations the * symbol indicates the loss of the amino acid coding potential of the DNA sequence.
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design success rate and an average of 88.5% of the target
bases receiving adequate coverage across the samples.
90% of the bases have a coverage of at least 29% of the
mean coverage. The reproducibility of the capture is in-
dicated by the reported 0.84 and 0.90 average pairwise
correlation for the per base and per amplicon coverage
rates respectively across all the samples. In their whole
chromosome X exome resequencing experiment Mondal
et al. report an amplicon design success rate of 98% and a
subsequent capture success rate of 97.3% described as
the percentage of the target bases covered by at least
one read [24].
In a diagnostic resequencing effort for congenital deaf-
ness genes, carried out with the Raindance platform, the
authors indicate a primer design success rate for 99.9%
of the target bases and 95% of these bases reachingadequate coverage [25]. A diagnostic test for congenital
muscular dystrophy including some genes with high GC
nucleotide content is reporting 84 to 95% capture suc-
cess on the target region for the samples included in the
analysis [26]. Highly consistent in all these Raindance cap-
ture based publications is a large number of off-target or
unmappable reads ranging between 40 and 70% of the
total reads indicating some issues with off-target amplifi-
cation and the downstream library preparation or data
analysis procedure [23-26].
Literature on the capture success rate of both the
Ampliseq and Haloplex platform is, due to the novelty
of the platforms, limited. No publications exist elaborat-
ing on the performance characteristics of the platforms.
The underlying technology for the Haloplex platform is
described in a publication by Johansson et al. who men-
tion a high capture success rate of over 98% and an inter
Table 6 PTEN deletion detection
Amplicon Chip Sample name End point
fluorescence
Cq Mean coverage Min coverage Max coverage Coverage stdev
PTEN-4 chip1 Normal1 3409.9 19.9 766.1 66 1232 314.0
PTEN-4 chip1 Normal1 3219.8 20.1 494.6 40 800 204.5
PTEN-4 chip1 MCF7 3592.8 23.7 450.0 37 720 176.9
PTEN-4 chip1 MCF7 3204.2 23.2 520.2 42 879 216.8
PTEN-4 chip2 786-O 5000.1 22.4 732.0 57 1224 310.2
PTEN-4 chip2 HCT-15 4097.8 19.8 486.7 33 823 201.9
PTEN-4 chip2 MDA-MB-231 4508.4 19.2 386.4 29 643 159.5
PTEN-4 chip2 OVCAR-5 4188.0 19.9 282.8 19 452 107.8
PTEN-4 chip3 MOLT-4 3499.5 19.6 683.9 48 1094 272.9
PTEN-4 chip3 DU-145 4686.3 18.7 364.0 24 610 144.1
PTEN-4 chip3 SN12C 3725.0 19.0 234.9 23 388 90.1
PTEN-4 chip3 BT-549 4036.6 20.0 422.5 45 643 150.1
PTEN-4 chip4 IGROV-1 4000.3 20.0 409.0 35 626 141.1
PTEN-4 chip4 CCRF-CEM 0.0 40.0 0.4 0 2 0.7
PTEN-4 chip4 PC3 0.0 40.0 0.4 0 1 0.5
PTEN-4 chip4 HCT116 3906.9 20.1 627.4 62 1033 246.2
PTEN-4 chip5 Normal1 A 4424.1 20.2 611.7 58 984 245.1
PTEN-4 chip5 ACHN 3996.0 20.2 426.6 28 699 176.5
PTEN-4 chip5 HT-29 4239.3 20.2 256.0 26 396 90.6
PTEN-4 chip5 MCF7 4035.4 20.5 503.0 38 796 196.7
PTEN-4 chip6 Normal1 2955.7 20.5 602.4 39 1015 261.2
PTEN-4 chip6 Normal2 3482.0 20.7 378.8 33 613 145.4
PTEN-4 chip6 Normal2 3440.0 21.1 225.6 18 344 83.2
PTEN-4 chip6 RPMI-8226 3660.0 21.9 365.8 36 571 135.1
Consistent lack of coverage, end point fluorescence and Cq call for the 2 samples with large homozygous deletions in the PTEN gene, spanning the whole of
capture assay PTEN-4.
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samples in controlled circumstances [27].
The performance characteristics of our platform are
similar to, if not outperforming some of the best statis-
tics currently published on targeted resequencing.Table 7 SNP detection in technical replicates
Sample Capture reaction PCR
replicates
Total
variants
Total varia
(union)
Normal1 DNA Duplicate-A 2 145 168 (15 ind
Duplicate-B 2 133
Singelton-A 1 141
Singleton-B 1 143
MCF7 Duplicate-A 2 76 86 (16 ind
Duplicate-B 2 77
Singelton 1 84
Normal2 DNA Singelton-A 1 134 149 (14 ind
Singleton-B 1 133
The number of consistently and inconsistently called SNP positions across the technConsidering that our PCR assays were not optimized,
the 93.6 percentage reproducible assay enrichment suc-
cess rate can be considered high compared to competing
platforms. By performing some assay optimization, assay
replacement, or by including multiple assays for thents Variants in comon in between
all replicates (intersect)
Genotype
concordant
Genotype
discordant
les) 120 (10 indels) 118 (10 indels) 2
els) 72 (10 indels) 69 (10 indels) 3
els) 121 (11 indels) 119 (11 indels) 2
ical replicates included in this experiment.
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creased, which is important for diagnostic applications.
One major advantage over competing platforms is the
flexibility in the assay dispensing in the capture chips;
we can easily exchange badly performing assays with new
designs, or include additional targets of interest. The use
of individual qPCR reactions clearly resulted in a very high
coverage uniformity. This together with the high amplifi-
cation specificity and a high degree of successful read
mappings results in a highly efficient capture platform re-
ducing the amount of over sequencing needed to achieve
adequate coverage. A potential downside of these individual
PCR reactions can be the amount of DNA required to per-
form a capture reaction on a sample which scales linearly
with the number of targets a user wants to capture. Al-
though the amount of input DNA required for a single re-
action is low (360 pg) the capture of the maximum number
of 5184 targets on this platform is roughly 1800 ng which
might not be available for all diagnostic samples. However,
one may consider to introduce a sample pre-amplification
step, as successfully done in Sjöblom et al. [28].
The high mutation and SNP calling validation rates
show the potential of this platform to be integrated into
diagnostic workflows. Based on the platform we describe
here, WaferGen Biosystems meanwhile has developed a
low-cost target enrichment platform consisting of a
single-sample nanodispenser and a PCR system that is
able to run 2 chips at the same time. This platform is
compatible with different types of chips containing be-
tween 1296 and 5184 PCR reactions, making it possible
to run more than 50,000 single PCR capture reactions
per day. The discordance in the SNP calling for the tech-
nical replicates warrants a note of caution in applying
captured resequencing platforms in routine diagnostics
without proper validation. No adequate sensitivity or
specificity assessment for any next generation capture
and sequencing platform currently exist and thus we
have no means of comparing our statistics to the ones
of competing platforms. We would like to urge other
researchers to include technical replicates in their evalu-
ation of any next generation sequencing platform, espe-
cially when aiming to design workflows with potential
diagnostic applications.
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